Hemodynamically significant perivalvular regurgitation affects about 1.5% of all prosthetic valve implants. Reoperation carries increased risk—especially in the setting of concomitant comorbidities of left ventricular dysfunction, prior coronary artery bypass grafts, renal dysfunction, and advanced age. Transcatheter closure of the perivalvular regurgitant channel using a variety of occluders has been available for several years; however, recent improvements in technology and technique have made this therapy more effective and available to a wider group of patients. This article describes the recent advances and the state of the art of this therapy.
Grunkeimeier GL, Jin R., Im K., Holubkov R., Kennard ED, Schaff HVTime-related risk of the St. Jude Silzone heart valve. Eur J Cardiothoracic Surg. 2006 ;30:20-27.
2.
Echevarria JR , Bernal JM, Rabasa JM, Morales D., Revilla Y., Revuelta JMReoperation for bioprosthetic valve dysfunction: a decade of clinical experience. Eur J Cardiothoracic Surg . 1991;5:523-526.
3.
Hourihan M., Perry SB, Mandell VS, et al. Transcatheter umbrella closure of valvular and perivalvular leaks. J Am Coll Cardiol. 1992;20:1371-1377.
Hildick-Smith D., Behan MW, De Giovanni J.Percutaneous closure of an aortic perivalvular leak via the transradial approach. Catheter Cardiovasc Interv . 2007;69:708-710.
6.
Pate GE, Al Zubaidi A., Chandavimol M., Thompson CR, Munt BI, Webb JGPercutaneous closure of prosthetic paralvular leaks: case series and review . Catheter Cardiovasc Interv. 2006;68:528-533.
7.
Hein R., Lang K., Wunderlich N., Wilson N., Sievert H.Percutaneous closure of perivalvular leaks. J Interv Cardiol . 2006; 19:S73-S77.
